Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 8/20 | 0.32 |
| ▸ | CTSC | P53634 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.31 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | GRM8 | O00222 | 2/20 | 0.31 |
| ▸ | GRM6 | O15303 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4190764 | 1.00 | GRM4 (0.32) | GRM4CTSCCYP2C19GRM2GRM3 | |
| SCHEMBL21013695 | 1.00 | GRM4 (0.32) | GRM4CTSCCYP2C19GRM2GRM3 | |
| SCHEMBL4186248 | 1.00 | GRM4 (0.32) | GRM4CTSCCYP2C19GRM2GRM3 | |
| SCHEMBL16064857 | 1.00 | GRM4 (0.32) | GRM4CTSCCYP2C19GRM2GRM3 | |
| SCHEMBL16064984 | 1.00 | GRM4 (0.32) | GRM4CTSCCYP2C19GRM2GRM3 | |
| SCHEMBL16064929 | 0.88 | CTSC (0.33) | GRM4CTSCCYP1A2 | |
| SCHEMBL21013699 | 0.88 | CTSC (0.33) | GRM4CTSCCYP1A2 | |
| SCHEMBL901728 | 0.87 | SLC6A9 (0.32) | — | |
| SCHEMBL7839416 | 0.73 | CTSC (0.31) | CTSCMEN1KMT2A | |
| SCHEMBL9738407 | 0.72 | CTSC (0.31) | CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2945952-B1 | HETEROCYCLE-SUBSTITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2019-08-28 | — | — | EP | disclosed |
| US-20190002480-A1 | Silane-Containing Heterocyclic Compounds and Methods of Use Thereof for the Treatment of Viral Diseases | MERCK SHARP & DOHME CORP. (US) | 2019-01-03 | — | — | US | disclosed |
| EP-2621279-B1 | FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2018-04-04 | — | — | EP | disclosed |
| US-9555038-B2 | Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9504690-B2 | Tetracyclic xanthene derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-11-29 | — | — | US | disclosed |
| EP-2685984-B1 | TETRACYCLIC XANTHENE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2016-11-02 | — | — | EP | disclosed |
| US-20160257697-A1 | THIOPHENE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OFUSE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2016-09-08 | — | — | US | disclosed |
| US-9254292-B2 | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-02-09 | — | — | US | disclosed |
| US-20150335648-A1 | HETEROCYCLE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | US | disclosed |
| WO-2014110687-A1 | THIAZOLYL-SUBSTITUED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | WO | disclosed |
| EP-2621932-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS FOR TREATING HEPATITIS C VIRAL INFECTION | Merck Sharp & Dohme Corp. (US) | 2013-08-07 | — | — | EP | disclosed |
| EP-2621931-A1 | TETRACYCLIC INDOLE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | Merck Sharp & Dohme Corp. (US) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012122716-A1 | TETRACYCLIC XANTHENE DERIVATIVES AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012125926-A2 | TETRACYCLIC XANTHENE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP (US) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012041014-A1 | TETRACYCLIC INDOLE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012040923-A1 | TETRACYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012041227-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS FOR TREATING HEPATITIS C VIRAL INFECTION | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012040924-A1 | FUSED TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2009029375-A1 | NOVEL INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20090062268-A1 | NOVEL INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257697-A1 | THIOPHENE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OFUSE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | HAVCR2, TPMT, RPL35 | GRM4 4652/4885CTSC 2240/4885CYP2C19 32/4885 |
| US-20190002480-A1 | Silane-Containing Heterocyclic Compounds and Methods of Use Thereof for the Treatment of Viral Diseases | HAVCR2, SULT2A1, HBB | GRM4 4777/4885CTSC 3032/4885CYP2C19 516/4885 |
| US-20090062268-A1 | NOVEL INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP11, PARP2 | GRM4 4687/4885CTSC 1189/4885CYP2C19 1800/4885 |
| US-20150335648-A1 | HETEROCYCLE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | HAVCR2, HCCS, CYP3A43 | GRM4 4858/4885CTSC 1127/4885CYP2C19 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.